| Print
Diamyd Medical AB ser. B (DMYD B)
This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Company profile
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company's activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
Address
Forecast key dates
| Name | Key Date |
|---|---|
| Diamyd Medical AB Annual General Meeting for 2026 | 2026-12-04T15:00:00 |
| Diamyd Medical AB Annual Report for 2026 | 2026-11-13T00:00:00 |
| Diamyd Medical AB Fourth Quarter Earnings Results for 2026 | 2026-10-07T00:00:00 |
| Diamyd Medical AB Third Quarter Earnings Results for 2026 | 2026-06-24T00:00:00 |
| Diamyd Medical AB Second Quarter Earnings Results for 2026 | 2026-03-25T00:00:00 |
| Diamyd Medical AB First Quarter Earnings Results for 2026 | 2026-01-28T00:00:00 |
| Diamyd Medical AB Annual General Meeting for 2025 | 2025-12-04T15:00:00 |
Previous key dates
| Name | Key Date |
|---|---|
| Diamyd Medical AB Annual General Meeting for 2025 | 2025-12-04T15:00:00 |
| Diamyd Medical AB Annual Report for 2025 | 2025-11-13T00:00:00 |
| Diamyd Medical AB Fourth Quarter Earnings Results for 2025 | 2025-10-08T00:00:00 |
| Diamyd Medical AB Third Quarter Earnings Results for 2025 | 2025-06-25T00:00:00 |
| Diamyd Medical AB Second Quarter Earnings Results for 2025 | 2025-04-09T00:00:00 |
| Diamyd Medical AB First Quarter Earnings Results for 2025 | 2025-01-29T00:00:00 |
| Diamyd Medical AB Annual General Meeting for 2024 | 2024-12-05T15:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2025 AJ Bell. All rights reserved.